Activity Provided By:

ACHL

Advances & Controversies in Malignant Hematology & Oncology: Solid Tumor Expert Insights

Overview / Abstract:	Advances & Controversies in Malignant Hematology & Oncology is a one-day comprehensive meeting that presents the latest data and cutting-edge updates in the rapidly evolving fields of malignant hematology and oncology. Advances & Controversies is unique in that it addresses questions and controversies emerging from the American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO) and other major disease-specific conferences. Faculty from Advances & Controversies were interviewed and asked to engage in a commentary style recording so that individuals who could not participate in the live conference can still benefit from these teachings/learnings. This program compiles those interviews in a viewer-friendly webcast presentation with a focus on solid tumors. Program topics include: Updates in Breast Cancer Kidney Cancer: Present & Future Updates in Head & Neck Cancer Updates in Gynecologic Oncology Lung Cancer: Present & Future Updates in Melanoma Pancreatic & Hepatobiliary Cancers: Are We Making Progress? Updates in Colorectal Cancer This activity is intended to meet the educational needs of healthcare providers involved in the care of oncology patients, including medical and surgical oncologists, hematologists, radiation oncologists and diagnostic radiologists, pathologists, oncology fellows and resident trainees, advanced care practitioners, physician assistants, nurses, naturopathic physicians and pharmacists. Upon participating in this activity, individuals will be able to: • Discuss new data emerging from ASH, ASCO and major disease-specific conferences and implications on the current standards of care* • Describe how genetic and cellular abnormalities influence disease severity and therapy selection • Formulate strategies to help mitigate therapy-related adverse events and/or toxicities • Review how to initiate and individualize therapy • Utilize current standards of care for patients with cancer Pharmacist Learning Objectives: Upon participating in this event, pharmacists will be able to: • Formulate strategies to help mitigate therapy-related adverse events and/or toxicities • Review how to initiate and individualize therapy *This educational program is not an official program of ASH or ASCO, nor is it endorsed by ASH or ASCO.
Expiration	Dec 09, 2017
Discipline(s)	Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME
Format	Online, Webinar / Webcast / Video
Credits / Hours	Physicians: 1.0 AMA PRA Category 1 Credit™. Nurses: 0.10 IACET CEUs. Pharmacists: 1.0 contact hours.
Accreditation	Physicians: The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses: ACHL is authorized by IACET to offer 0.10 CEU for this program. IACET CEUs are accepted by the American Nursing Association. Contact your licensing agency for details. 0.10 CEU = 60 minutes. Pharmacists: This activity has been approved for 1.0 contact hours.
Presenters / Authors / Faculty	Maurie Markman, MD (Program Chair) President of Medicine & Science Cancer Treatment Centers of America Al B. Benson III, MD, FACP, FASCO Professor of Medicine, Division of Hematology/ Oncology, Feinberg School of Medicine Associate Director for Cooperative Groups Robert H. Lurie Comprehensive Cancer Center Northwestern University Chicago, IL Edward Chu, MD Professor of Medicine and Chief Division of Hematology-Oncology University of Pittsburgh School of Medicine Deputy Director University of Pittsburgh Cancer Institute Pittsburgh, PA Kim A. Margolin, MD Clinical Professor Department of Medical Oncology and Therapeutics Research, City of Hope Medical Center Duarte, CA Robert J. Motzer, MD Attending Physician Genitourinary Oncology Section, Memorial Sloan Kettering Cancer Center New York, NY Hope S. Rugo, MD Professor of Medicine and Director Breast Oncology and Clinical Trials Education Helen Diller Family Comprehensive Cancer Center University of California San Francisco San Francisco, CA Ravi Salgia, MD, PhD Professor and Chair Associate Director of Clinical Sciences Medical Oncology and Therapeutics Research City of Hope Medical Center Duarte, CA Everett E. Vokes, MD John E. Ultmann Professor and Chairman Department of Medicine University of Chicago Physician-in-Chief University of Chicago Medicine Chicago, IL
Sponsors / Supporters / Grant Providers	This activity is sponsored by Cancer Treatment Centers of America.
Keywords / Search Terms	ACHL, Cancer Treatment Centers of America, CTCA, Hematology, Oncology, ASH, ASCO, Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map